Program
Lutetium Lu 177 Ludotadipep
Also written as “[177Lu]Ludotadipep” and “[177-Lu]Ludotadipep”.
Its studies are mostly in Prostatic Neoplasms, led by FutureChem.
Furthest: phase 3, since Apr 15, 20263 company-led studies, 2 open or runningNext primary completion: Mar 26, 2028 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| FutureChem | 32 open or running | phase 3since Apr 15, 2026 | Jul 7, 2020 | Mar 26, 2028phase 3 · NCT07853209 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 7, 2020First study: phase 1 study in Prostatic NeoplasmsFirst studyNCT04509557 · 30 enrolled · Korea, Republic of
- Oct 6, 2022Phase 2 study in Prostatic NeoplasmsNCT05579184 · 20 enrolled · Korea, Republic of
- Apr 15, 2026Phase 3 study in Prostatic NeoplasmsPhase 3 reachedNCT07853209 · 114 planned · South Korea
Ahead
- Mar 26, 2028Primary completion: phase 3 study in Prostatic NeoplasmsNCT07853209
TargetBeta
FOLH1 →read by rule
“A radioconjugate composed of ludotadipep, a prostate-specific membrane antigen (PSMA)-targeting agent, ”NCIt, by rule
Other programs on FOLH1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| flotufolastat F 18rule | Bracco | phase 4 | 7 |
| piflufolastatrule | Lantheus | phase 4 | 5 |
| abefolastat tesaroxetan CU-64rule | clarity-pharmaceuticals-ltd | phase 3 | 5 |
| gallium 68 PSMA-11rule | Novartis | phase 3 | 4 |
| Anti-PSMA/Anti-CD28 Bispecific Antibody JNJ-87189401 | Johnson & Johnson | phase 3 | 2 |
| Lutetium Lu 177 NYM032rule | Norroy Bioscience | phase 3 | 2 |
| actinium AC-225 vipivotide tetraxetan | Novartis | phase 3 | 2 |
| HRS-4357 | Jiangsu HengRui Medicine | phase 3 | 2 |
| zadavotide guraxetan | AstraZeneca | phase 2 | 4 |
| AB-001rule | frontier-biotechnologies-inc | phase 2 | 3 |
| olsutamigrule | Regeneron Pharmaceuticals | phase 2 | 2 |
| SHR-4394 | Jiangsu HengRui Medicine | phase 2 | 2 |
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07853209Prostatic Neoplasms · South Korea | 3 | Recruiting | Mar 26, 2028 | 114 |
| NCT05579184Prostatic Neoplasms · Korea, Republic of | 2 | Active, not recruiting | Dec 31, 2024 | 20 |
| NCT04509557Prostatic Neoplasms · Korea, Republic of | 1 | Completed | Jun 30, 2022 | 30 |
How it is read
Names in the registry
- “[177Lu]Ludotadipep”, 2 entries
- “[177-Lu]Ludotadipep”, 1 entry
Conditions, from the studies’ own filings
- Prostatic Neoplasms, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.